INOVIQ Ltd (ASX:IIQ) Builds Next-Generation Cancer Technology Pipeline

Aditi Sarkar

23 September 2026 05:32 AM AEST

INOVIQ Ltd (ASX:IIQ) Builds Next-Generation Cancer Technology Pipeline

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

INOVIQ continued development of EXO-OC™ ovarian cancer diagnostic toward US Laboratory Developed Test commercialisation.
CAR-exosome programs demonstrated preclinical tumour-killing activity across multiple cancer models.
EXO-NET® customer base expanded globally through distribution partner Promega.
INOVIQ ended FY26 with cash and cash equivalents of $9.35 million.

INOVIQ Ltd (ASX:IIQ) is a biotechnology company developing next-generation diagnostics and therapeutics based on proprietary exosome technologies. The company’s portfolio includes commercial exosome isolation products, cancer diagnostics and preclinical exosome-based therapeutics. During FY26, INOVIQ focused on advancing EXO-OC™, progressing CAR-exosome research and expanding commercial activities around EXO-NET®.

EXO-OC™ Development Continues Toward Commercial Pathway

INOVIQ’s EXO-OC™ is an exosome-based blood test being developed for early detection of ovarian cancer. The test uses EXO-NET® technology to isolate exosomes and combines exosomal miRNA biomarkers with plasma CA125 through an AI and Machine Learning algorithm.

During FY26, INOVIQ conducted an expanded clinical validation study using biobanked plasma samples. The company reported that the study could not be used for clinical validation due to sample quality issues associated with commercially sourced biobank samples.

INOVIQ stated that these issues were unrelated to EXO-NET® technology or the EXO-OC™ test. Future validation studies are planned using standardised sample collection protocols.

CAR-Exosome Therapeutics Advance Through Preclinical Studies

INOVIQ is developing CAR-exosomes as a next-generation cell-free therapeutic approach for solid tumours. The technology is designed to combine tumour targeting and cancer-killing capabilities with potential Manufacturing advantages.

During FY26, the company reported preclinical progress across breast, lung and ovarian cancer models. INOVIQ continues advancing manufacturing readiness and optimisation activities supporting future clinical development.

Commercial Platform and Financial Position

INOVIQ expanded EXO-NET® commercial activities through global distribution partner Promega. The EXO-NET® customer base reached 90 customers across academic institutions, government institutes, biopharma companies and clinical laboratories.

The company reported FY26 Revenue from EXO-NET® of $138,045 and hTERT test revenue of $294,002. INOVIQ recorded a net loss of $7.5 million and ended FY26 with cash and cash equivalents of $9.35 million.

FY27 priorities include EXO-OC™ validation, LDT readiness, CAR-exosome manufacturing capability and commercial partnerships.

Key Insights

INOVIQ is advancing an exosome-based healthcare platform spanning diagnostics and therapeutics. FY26 activities focused on EXO-OC™ development, CAR-exosome research, EXO-NET® commercial expansion and future clinical milestones.

FAQs

Q:What does INOVIQ develop?

A:INOVIQ develops exosome-based diagnostics and therapeutics for cancer applications.

Q:What is EXO-OC™?

A:EXO-OC™ is an exosome-based blood test being developed for early detection of ovarian cancer.

Q:What are CAR-exosomes?

A:CAR-exosomes are engineered exosome-based therapeutics designed to target solid tumours.

Q:What is EXO-NET®?

A:EXO-NET® is INOVIQ’s proprietary exosome isolation technology.

Q:What was INOVIQ’s FY26 cash position?

A:INOVIQ reported cash and cash equivalents of $9.35 million at 30 June 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.